Imugene Reports First Complete Response in BTKi Cohort
Key points
- First patient in BTKi cohort achieved complete response
- Patient had previously failed BTKi therapy
- BTKi therapy addresses a $12.0 billion global market
Full summary
Imugene Limited (ASX: IMU) reports the first complete response in the concurrent BTKi cohort of its ongoing azer-cel Phase 1b trial. The patient, a Follicular Lymphoma (FL) patient who had previously failed BTKi therapy, achieved a complete response at the Day 28 assessment. This cohort evaluates whether concurrent dosing of azer-cel with a BTKi may restore or enhance therapeutic activity in patients who have relapsed on or are refractory to BTKi therapy. The global BTKi market reached approximately US$12.0 billion in 2025. The trial is ongoing across ten US and five Australian sites.
Outlook
Imugene believes this combination approach could represent a meaningful development pathway for azer-cel.
Summary generated by a large language model. Please interpret with care.